R-Pharm will launch production of Sputnik V vaccine by the end of January


R-Pharm, Russian pharmaceutical company will launch the production of COVID-19 vaccine Sputnik V by the end of January, RIA Novosti reports with reference to the head of the Russian Ministry of Industry and Trade Denis Manturov.

“We selected seven sites, six of which are functioning. This is site of Gamalei Institute – three production sites, Generium, Biocad and Binnofarm, and R-Farm will join the work by the end of the month”, said Denis Manturov.

Russian Deputy Prime Minister Tatyana Golikova added that large-scale production of another Russian COVID-19 vaccine EpiVakKoron, of the Vector center, will start.

“The Sputnik V vaccine has already been used on a large scale. The “EpiVakKorona” of the “Vector” center enter the civil circulation and be used to vaccinate the population. At the same time, large-scale production will be provided starting in February 2021″, said Golikova.

In August, the Ministry of Health of Russia registered the world’s first vaccine for the prevention of COVID-19, developed by the Gamalei Research Center. It was called Sputnik V. The vaccine was created on a studied and tested platform of human adenoviral vectors.